Christopher D. Alafi, Director at Intra-Cellular Therapies, Inc. (ITCI), bought 100,000 shares at $12.56 ($1.3M) on 2019-05-14, disclosed to the SEC on 2019-05-15.
Open-market purchase of $1.3M ITCI by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| ITCI | BUY | 2020-09-14 | $1.5M | — | Filing → |
| ITCI | BUY | 2020-09-11 | $590K | — | Filing → |
| ITCI | BUY | 2019-09-11 | $9.8M | — | Filing → |